Clinical Trial Search

Primary: Number of Patients Requiring Continuous Lorazepam Infusion — 2; 16 participants

Primary: Retention in Treatment — 28 Participants — p=0.0021

Primary: Mean Length of Hospital Stay — 44.91; 50.50 hours

Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine

Primary: Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal — 180.5; 112.5; 109.1 mg — p=0.64

Primary: Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups — 14.1; 124.4 mg of benzodiazepine per 8 hours

Primary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale

Primary: Drinking — 6; 8; 2 participants — p=<0.04

Primary: Negative Affect — 2.91; 2.47 units — p=.62

Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03

Primary: Treatment Adherence — 15 Participants

Primary: Total Lorazepam Dosage (in Milligrams) — 16.5; 3.4 milligrams of lorazepam

Primary: Withdrawal Symptoms Measured Using the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) — 4.16; 6.57 score on a scale — p=0.067

Primary: Breath Alcohol — 0.001; 0.075; 0.001; 0.071 gr/dL — p=0.28

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — 198.3; 55.9 ng/mg

Primary: Craving to Drink — 36.5; 42.9 units on a scale — p=.003

Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065

Primary: Visual Analogue Scale (VAS) of Craving Severity: 2 Arms — 2.38; 1.44 score on a scale

Primary: Change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA) Score — -2.76; 1.01 units on a scale

Primary: Intervention Effects on Brain Functional Connectivity — 0.05; 0.19 percentage of Blood Oxygenation Level De

Primary: Alcohol Consumption — 92.0; 77.3 mg/%

Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants

Primary: Visual Analog Scale of Craving to Drink at 1 Week Following Administration of Fenofibrate or Placebo During the Double-Blind Period — 8.94; 10.37; 9.83; 11.03 units on a…

Primary: Clinical Global Impression Scale-I (CGI-I) — 3.65; 3.81; 3.86; 4.05 units on a scale

Primary: Weekly Percentage of Heavy Drinking Days — 37.9; 48.4 percentage of heavy drinking days

Primary: Change From Baseline in Drinking Quantity and Frequency Using Drinks Per Week at Week 12 — 42.07; 56.67; 41.20; 9.16 drinks/week

Primary: Alcohol Craving in Response to the Alcohol Cue Script — 12.7; 10.7 Units on a scale

Primary: Change in Blood Oxygen Level Dependent (BOLD) fMRI Signal for Alcohol Versus Non-alcohol Stimuli — 0.267390; 0.040281; 0.058670; -0.069048 BOLD response

Primary: Percent of Heavy Drinking Days Per Week — 22.5; 53.9 percent of heavy drinking days

Primary: Change in Salivary Progesterone Level — 237.86; 97.87 pg/ml